LianBio (LIANY)
OTCMKTS
· Delayed Price · Currency is USD
0.122
0.00 (0.00%)
Apr 29, 2026, 10:34 AM EST
LianBio Company Description
LianBio, operates as a biotechnology company in China and other Asian countries.
It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications.
The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 gene amplification; and BBP-398 for solid tumors.
The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
LianBio
| Country | Cayman Islands |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 163 |
| CEO | Adam Stone |
Contact Details
Address: 103 Carnegie Center Drive Princeton, New Jersey 08540 United States | |
| Phone | 609 486 2308 |
| Website | lianbio.com |
Stock Details
| Ticker Symbol | LIANY |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US53000N1081 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Adam Leo Stone | Interim Chief Executive Officer and Director |
| Konstantin Poukalov | Founder and Executive Chairman |
| Ehong Gu | Interim Chief Financial Officer, Vice President and Head of Global Finance |
| Ji Chen | Senior Vice President and General Counsel |
| Brianne Jahn | Chief Business Officer |
| Levvy Lv D. Eng | Senior Vice President and Global Head of Development |